Progress + Pipeline
Progress
In Gliobastoma
The PI3Kinase pathway play a role in cell metabolism, growth, proliferation, and survival. Many researchers believe that inhibiting this pathway could be a promising cancer treatment. This pathway is over-expressed in nearly half of all human cancers.
The graph to the left demonstrates the results from research conducted by Drs. Ekokobe Fonkem and Chad Quarles at the Barrow Neurological Institute. Data shows that our compound causes growth arrest of GL261 tumor cells.
.
These graphs show that the combination of our GCT-007 compound and PDL1 result in a significant reduction of tumor volume.
.
In DIPG
We will continue additional trials using GCT-007 in DIPG Human cell lines.
Graphs show cell viability % for various DIPG cell lines when treated with GCT-007.
In Breast Cancer
The Company is also exploring the use of its second licensed compound, GCT-008, which is a potent, selective and orally bioavailable inhibitor of VPS34.
Trials Ahead
We have mapped out an anticipated timeline for our unique PI3K inhibitor based on results that we have collected in our preclinical laboratory studies. Based on initial findings, our unique compound appears to have inhibition potential to slow the onset – or potentially reverse – the development of cancer tumors in the brain (glioblastoma) and in the breast (triple negative).
The Company is also exploring the use of its second licensed compound, GCT-008, which is a potent, selective and orally bioavailable inhibitor of VPS34.